Samit Hirawat (Bristol Myers Squibb)

#ASH20: As Bris­tol My­ers awaits FDA word, the CAR-T BC­MA lead­ers go head-to-head once again. This time, they're not alone

In 2017, when Nan­jing’s Leg­end Biotech first para­chut­ed on­to AS­CO with stun­ning BC­MA CAR-T da­ta, blue­bird bio, the in­cum­bents in the field, im­me­di­ate­ly crit­i­cized their tri­al: “It’s a very dif­fer­ent pa­tient pop­u­la­tion,” blue­bird chief Nick Leschly said at the time.

Three years and mul­ti­ple rounds of con­fir­ma­to­ry Leg­end da­ta lat­er, lead­er­ship at Bris­tol My­ers Squibb, which took the lead on blue­bird’s ide-cel fol­low­ing their Cel­gene buy­out, of­fer a dif­fer­ent tune when asked about com­peti­tors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.